Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis

Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or observation in several randomized controlled trials (RCTs) of patients with newly diagnosed multiple myeloma (NDMM). All studies had PFS...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of clinical oncology Vol. 35; no. 29; p. 3279
Main Authors:	McCarthy, Philip L, Holstein, Sarah A, Petrucci, Maria Teresa, Richardson, Paul G, Hulin, Cyrille, Tosi, Patrizia, Bringhen, Sara, Musto, Pellegrino, Anderson, Kenneth C, Caillot, Denis, Gay, Francesca, Moreau, Philippe, Marit, Gerald, Jung, Sin-Ho, Yu, Zhinuan, Winograd, Benjamin, Knight, Robert D, Palumbo, Antonio, Attal, Michel
Format:	Journal Article
Language:	English
Published:	United States 10.10.2017
Subjects:	Adult Aged Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - adverse effects Chemotherapy, Adjuvant Disease Progression Disease-Free Survival Drug Administration Schedule Female Humans Kaplan-Meier Estimate Lenalidomide Maintenance Chemotherapy Male Middle Aged Multiple Myeloma - diagnosis Multiple Myeloma - mortality Multiple Myeloma - therapy Randomized Controlled Trials as Topic Risk Factors Stem Cell Transplantation - adverse effects Stem Cell Transplantation - mortality Thalidomide - administration & dosage Thalidomide - adverse effects Thalidomide - analogs & derivatives Time Factors Transplantation, Autologous Treatment Outcome Young Adult
ISSN:	1527-7755, 1527-7755
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or observation in several randomized controlled trials (RCTs) of patients with newly diagnosed multiple myeloma (NDMM). All studies had PFS as the primary end point, and none were powered for overall survival (OS) as a primary end point. Thus, a meta-analysis was conducted to better understand the impact of lenalidomide maintenance in this setting. Patients and Methods The meta-analysis was conducted using primary-source patient-level data and documentation from three RCTs (Cancer and Leukemia Group B 100104, Gruppo Italiano Malattie Ematologiche dell'Adulto RV-MM-PI-209, and Intergroupe Francophone du Myélome 2005-02) that met the following prespecified inclusion criteria: an RCT in patients with NDMM receiving ASCT followed by lenalidomide maintenance versus placebo or observation with patient-level data available and achieved database lock for primary efficacy analysis. Results Overall, 1,208 patients were included in the meta-analysis (605 patients in the lenalidomide maintenance group and 603 in the placebo or observation group). The median PFS was 52.8 months for the lenalidomide group and 23.5 months for the placebo or observation group (hazard ratio, 0.48; 95% CI, 0.41 to 0.55). At a median follow-up time of 79.5 months for all surviving patients, the median OS had not been reached for the lenalidomide maintenance group, whereas it was 86.0 months for the placebo or observation group (hazard ratio, 0.75; 95% CI, 0.63 to 0.90; P = .001). The cumulative incidence rate of a second primary malignancy before disease progression was higher with lenalidomide maintenance versus placebo or observation, whereas the cumulative incidence rates of progression, death, or death as a result of myeloma were all higher with placebo or observation versus lenalidomide maintenance. Conclusion This meta-analysis demonstrates a significant OS benefit and confirms the PFS benefit with lenalidomide maintenance after ASCT in patients with NDMM when compared with placebo or observation.
AbstractList	Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or observation in several randomized controlled trials (RCTs) of patients with newly diagnosed multiple myeloma (NDMM). All studies had PFS as the primary end point, and none were powered for overall survival (OS) as a primary end point. Thus, a meta-analysis was conducted to better understand the impact of lenalidomide maintenance in this setting. Patients and Methods The meta-analysis was conducted using primary-source patient-level data and documentation from three RCTs (Cancer and Leukemia Group B 100104, Gruppo Italiano Malattie Ematologiche dell'Adulto RV-MM-PI-209, and Intergroupe Francophone du Myélome 2005-02) that met the following prespecified inclusion criteria: an RCT in patients with NDMM receiving ASCT followed by lenalidomide maintenance versus placebo or observation with patient-level data available and achieved database lock for primary efficacy analysis. Results Overall, 1,208 patients were included in the meta-analysis (605 patients in the lenalidomide maintenance group and 603 in the placebo or observation group). The median PFS was 52.8 months for the lenalidomide group and 23.5 months for the placebo or observation group (hazard ratio, 0.48; 95% CI, 0.41 to 0.55). At a median follow-up time of 79.5 months for all surviving patients, the median OS had not been reached for the lenalidomide maintenance group, whereas it was 86.0 months for the placebo or observation group (hazard ratio, 0.75; 95% CI, 0.63 to 0.90; P = .001). The cumulative incidence rate of a second primary malignancy before disease progression was higher with lenalidomide maintenance versus placebo or observation, whereas the cumulative incidence rates of progression, death, or death as a result of myeloma were all higher with placebo or observation versus lenalidomide maintenance. Conclusion This meta-analysis demonstrates a significant OS benefit and confirms the PFS benefit with lenalidomide maintenance after ASCT in patients with NDMM when compared with placebo or observation.Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or observation in several randomized controlled trials (RCTs) of patients with newly diagnosed multiple myeloma (NDMM). All studies had PFS as the primary end point, and none were powered for overall survival (OS) as a primary end point. Thus, a meta-analysis was conducted to better understand the impact of lenalidomide maintenance in this setting. Patients and Methods The meta-analysis was conducted using primary-source patient-level data and documentation from three RCTs (Cancer and Leukemia Group B 100104, Gruppo Italiano Malattie Ematologiche dell'Adulto RV-MM-PI-209, and Intergroupe Francophone du Myélome 2005-02) that met the following prespecified inclusion criteria: an RCT in patients with NDMM receiving ASCT followed by lenalidomide maintenance versus placebo or observation with patient-level data available and achieved database lock for primary efficacy analysis. Results Overall, 1,208 patients were included in the meta-analysis (605 patients in the lenalidomide maintenance group and 603 in the placebo or observation group). The median PFS was 52.8 months for the lenalidomide group and 23.5 months for the placebo or observation group (hazard ratio, 0.48; 95% CI, 0.41 to 0.55). At a median follow-up time of 79.5 months for all surviving patients, the median OS had not been reached for the lenalidomide maintenance group, whereas it was 86.0 months for the placebo or observation group (hazard ratio, 0.75; 95% CI, 0.63 to 0.90; P = .001). The cumulative incidence rate of a second primary malignancy before disease progression was higher with lenalidomide maintenance versus placebo or observation, whereas the cumulative incidence rates of progression, death, or death as a result of myeloma were all higher with placebo or observation versus lenalidomide maintenance. Conclusion This meta-analysis demonstrates a significant OS benefit and confirms the PFS benefit with lenalidomide maintenance after ASCT in patients with NDMM when compared with placebo or observation. Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated prolonged progression-free survival (PFS) versus placebo or observation in several randomized controlled trials (RCTs) of patients with newly diagnosed multiple myeloma (NDMM). All studies had PFS as the primary end point, and none were powered for overall survival (OS) as a primary end point. Thus, a meta-analysis was conducted to better understand the impact of lenalidomide maintenance in this setting. Patients and Methods The meta-analysis was conducted using primary-source patient-level data and documentation from three RCTs (Cancer and Leukemia Group B 100104, Gruppo Italiano Malattie Ematologiche dell'Adulto RV-MM-PI-209, and Intergroupe Francophone du Myélome 2005-02) that met the following prespecified inclusion criteria: an RCT in patients with NDMM receiving ASCT followed by lenalidomide maintenance versus placebo or observation with patient-level data available and achieved database lock for primary efficacy analysis. Results Overall, 1,208 patients were included in the meta-analysis (605 patients in the lenalidomide maintenance group and 603 in the placebo or observation group). The median PFS was 52.8 months for the lenalidomide group and 23.5 months for the placebo or observation group (hazard ratio, 0.48; 95% CI, 0.41 to 0.55). At a median follow-up time of 79.5 months for all surviving patients, the median OS had not been reached for the lenalidomide maintenance group, whereas it was 86.0 months for the placebo or observation group (hazard ratio, 0.75; 95% CI, 0.63 to 0.90; P = .001). The cumulative incidence rate of a second primary malignancy before disease progression was higher with lenalidomide maintenance versus placebo or observation, whereas the cumulative incidence rates of progression, death, or death as a result of myeloma were all higher with placebo or observation versus lenalidomide maintenance. Conclusion This meta-analysis demonstrates a significant OS benefit and confirms the PFS benefit with lenalidomide maintenance after ASCT in patients with NDMM when compared with placebo or observation.
Author	Yu, Zhinuan McCarthy, Philip L Holstein, Sarah A Moreau, Philippe Palumbo, Antonio Attal, Michel Musto, Pellegrino Caillot, Denis Knight, Robert D Hulin, Cyrille Gay, Francesca Bringhen, Sara Winograd, Benjamin Petrucci, Maria Teresa Jung, Sin-Ho Marit, Gerald Anderson, Kenneth C Richardson, Paul G Tosi, Patrizia
Author_xml	– sequence: 1 givenname: Philip L surname: McCarthy fullname: McCarthy, Philip L organization: Philip L. McCarthy, Roswell Park Cancer Institute, Buffalo, NY; Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; Maria Teresa Petrucci, University La Sapienza; Antonio Palumbo, Takeda Italia, Rome; Patrizia Tosi, Rimini Hospital, Rimini; Sara Bringhen and Francesca Gay, University of Torino, Torino; Pellegrino Musto, Cancer Institute for Research and Care and The Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; Cyrille Hulin and Gerald Marit, Bordeaux Centre Hospitalier Universitaire, Bordeaux; Denis Caillot, Dijon University Hospital Center, Dijon; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes; Michel Attal, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Sin-Ho Jung, Duke University, Durham, NC; and Zhinuan Yu, Benjamin Winograd, and Robert D. Knight, Celgene Corporation, Summit, NJ – sequence: 2 givenname: Sarah A surname: Holstein fullname: Holstein, Sarah A organization: Philip L. McCarthy, Roswell Park Cancer Institute, Buffalo, NY; Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; Maria Teresa Petrucci, University La Sapienza; Antonio Palumbo, Takeda Italia, Rome; Patrizia Tosi, Rimini Hospital, Rimini; Sara Bringhen and Francesca Gay, University of Torino, Torino; Pellegrino Musto, Cancer Institute for Research and Care and The Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; Cyrille Hulin and Gerald Marit, Bordeaux Centre Hospitalier Universitaire, Bordeaux; Denis Caillot, Dijon University Hospital Center, Dijon; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes; Michel Attal, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Sin-Ho Jung, Duke University, Durham, NC; and Zhinuan Yu, Benjamin Winograd, and Robert D. Knight, Celgene Corporation, Summit, NJ – sequence: 3 givenname: Maria Teresa surname: Petrucci fullname: Petrucci, Maria Teresa organization: Philip L. McCarthy, Roswell Park Cancer Institute, Buffalo, NY; Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; Maria Teresa Petrucci, University La Sapienza; Antonio Palumbo, Takeda Italia, Rome; Patrizia Tosi, Rimini Hospital, Rimini; Sara Bringhen and Francesca Gay, University of Torino, Torino; Pellegrino Musto, Cancer Institute for Research and Care and The Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; Cyrille Hulin and Gerald Marit, Bordeaux Centre Hospitalier Universitaire, Bordeaux; Denis Caillot, Dijon University Hospital Center, Dijon; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes; Michel Attal, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Sin-Ho Jung, Duke University, Durham, NC; and Zhinuan Yu, Benjamin Winograd, and Robert D. Knight, Celgene Corporation, Summit, NJ – sequence: 4 givenname: Paul G surname: Richardson fullname: Richardson, Paul G organization: Philip L. McCarthy, Roswell Park Cancer Institute, Buffalo, NY; Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; Maria Teresa Petrucci, University La Sapienza; Antonio Palumbo, Takeda Italia, Rome; Patrizia Tosi, Rimini Hospital, Rimini; Sara Bringhen and Francesca Gay, University of Torino, Torino; Pellegrino Musto, Cancer Institute for Research and Care and The Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; Cyrille Hulin and Gerald Marit, Bordeaux Centre Hospitalier Universitaire, Bordeaux; Denis Caillot, Dijon University Hospital Center, Dijon; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes; Michel Attal, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Sin-Ho Jung, Duke University, Durham, NC; and Zhinuan Yu, Benjamin Winograd, and Robert D. Knight, Celgene Corporation, Summit, NJ – sequence: 5 givenname: Cyrille surname: Hulin fullname: Hulin, Cyrille organization: Philip L. McCarthy, Roswell Park Cancer Institute, Buffalo, NY; Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; Maria Teresa Petrucci, University La Sapienza; Antonio Palumbo, Takeda Italia, Rome; Patrizia Tosi, Rimini Hospital, Rimini; Sara Bringhen and Francesca Gay, University of Torino, Torino; Pellegrino Musto, Cancer Institute for Research and Care and The Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; Cyrille Hulin and Gerald Marit, Bordeaux Centre Hospitalier Universitaire, Bordeaux; Denis Caillot, Dijon University Hospital Center, Dijon; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes; Michel Attal, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Sin-Ho Jung, Duke University, Durham, NC; and Zhinuan Yu, Benjamin Winograd, and Robert D. Knight, Celgene Corporation, Summit, NJ – sequence: 6 givenname: Patrizia surname: Tosi fullname: Tosi, Patrizia organization: Philip L. McCarthy, Roswell Park Cancer Institute, Buffalo, NY; Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; Maria Teresa Petrucci, University La Sapienza; Antonio Palumbo, Takeda Italia, Rome; Patrizia Tosi, Rimini Hospital, Rimini; Sara Bringhen and Francesca Gay, University of Torino, Torino; Pellegrino Musto, Cancer Institute for Research and Care and The Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; Cyrille Hulin and Gerald Marit, Bordeaux Centre Hospitalier Universitaire, Bordeaux; Denis Caillot, Dijon University Hospital Center, Dijon; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes; Michel Attal, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Sin-Ho Jung, Duke University, Durham, NC; and Zhinuan Yu, Benjamin Winograd, and Robert D. Knight, Celgene Corporation, Summit, NJ – sequence: 7 givenname: Sara surname: Bringhen fullname: Bringhen, Sara organization: Philip L. McCarthy, Roswell Park Cancer Institute, Buffalo, NY; Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; Maria Teresa Petrucci, University La Sapienza; Antonio Palumbo, Takeda Italia, Rome; Patrizia Tosi, Rimini Hospital, Rimini; Sara Bringhen and Francesca Gay, University of Torino, Torino; Pellegrino Musto, Cancer Institute for Research and Care and The Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; Cyrille Hulin and Gerald Marit, Bordeaux Centre Hospitalier Universitaire, Bordeaux; Denis Caillot, Dijon University Hospital Center, Dijon; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes; Michel Attal, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Sin-Ho Jung, Duke University, Durham, NC; and Zhinuan Yu, Benjamin Winograd, and Robert D. Knight, Celgene Corporation, Summit, NJ – sequence: 8 givenname: Pellegrino surname: Musto fullname: Musto, Pellegrino organization: Philip L. McCarthy, Roswell Park Cancer Institute, Buffalo, NY; Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; Maria Teresa Petrucci, University La Sapienza; Antonio Palumbo, Takeda Italia, Rome; Patrizia Tosi, Rimini Hospital, Rimini; Sara Bringhen and Francesca Gay, University of Torino, Torino; Pellegrino Musto, Cancer Institute for Research and Care and The Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; Cyrille Hulin and Gerald Marit, Bordeaux Centre Hospitalier Universitaire, Bordeaux; Denis Caillot, Dijon University Hospital Center, Dijon; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes; Michel Attal, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Sin-Ho Jung, Duke University, Durham, NC; and Zhinuan Yu, Benjamin Winograd, and Robert D. Knight, Celgene Corporation, Summit, NJ – sequence: 9 givenname: Kenneth C surname: Anderson fullname: Anderson, Kenneth C organization: Philip L. McCarthy, Roswell Park Cancer Institute, Buffalo, NY; Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; Maria Teresa Petrucci, University La Sapienza; Antonio Palumbo, Takeda Italia, Rome; Patrizia Tosi, Rimini Hospital, Rimini; Sara Bringhen and Francesca Gay, University of Torino, Torino; Pellegrino Musto, Cancer Institute for Research and Care and The Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; Cyrille Hulin and Gerald Marit, Bordeaux Centre Hospitalier Universitaire, Bordeaux; Denis Caillot, Dijon University Hospital Center, Dijon; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes; Michel Attal, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Sin-Ho Jung, Duke University, Durham, NC; and Zhinuan Yu, Benjamin Winograd, and Robert D. Knight, Celgene Corporation, Summit, NJ – sequence: 10 givenname: Denis surname: Caillot fullname: Caillot, Denis organization: Philip L. McCarthy, Roswell Park Cancer Institute, Buffalo, NY; Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; Maria Teresa Petrucci, University La Sapienza; Antonio Palumbo, Takeda Italia, Rome; Patrizia Tosi, Rimini Hospital, Rimini; Sara Bringhen and Francesca Gay, University of Torino, Torino; Pellegrino Musto, Cancer Institute for Research and Care and The Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; Cyrille Hulin and Gerald Marit, Bordeaux Centre Hospitalier Universitaire, Bordeaux; Denis Caillot, Dijon University Hospital Center, Dijon; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes; Michel Attal, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Sin-Ho Jung, Duke University, Durham, NC; and Zhinuan Yu, Benjamin Winograd, and Robert D. Knight, Celgene Corporation, Summit, NJ – sequence: 11 givenname: Francesca surname: Gay fullname: Gay, Francesca organization: Philip L. McCarthy, Roswell Park Cancer Institute, Buffalo, NY; Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; Maria Teresa Petrucci, University La Sapienza; Antonio Palumbo, Takeda Italia, Rome; Patrizia Tosi, Rimini Hospital, Rimini; Sara Bringhen and Francesca Gay, University of Torino, Torino; Pellegrino Musto, Cancer Institute for Research and Care and The Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; Cyrille Hulin and Gerald Marit, Bordeaux Centre Hospitalier Universitaire, Bordeaux; Denis Caillot, Dijon University Hospital Center, Dijon; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes; Michel Attal, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Sin-Ho Jung, Duke University, Durham, NC; and Zhinuan Yu, Benjamin Winograd, and Robert D. Knight, Celgene Corporation, Summit, NJ – sequence: 12 givenname: Philippe surname: Moreau fullname: Moreau, Philippe organization: Philip L. McCarthy, Roswell Park Cancer Institute, Buffalo, NY; Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; Maria Teresa Petrucci, University La Sapienza; Antonio Palumbo, Takeda Italia, Rome; Patrizia Tosi, Rimini Hospital, Rimini; Sara Bringhen and Francesca Gay, University of Torino, Torino; Pellegrino Musto, Cancer Institute for Research and Care and The Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; Cyrille Hulin and Gerald Marit, Bordeaux Centre Hospitalier Universitaire, Bordeaux; Denis Caillot, Dijon University Hospital Center, Dijon; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes; Michel Attal, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Sin-Ho Jung, Duke University, Durham, NC; and Zhinuan Yu, Benjamin Winograd, and Robert D. Knight, Celgene Corporation, Summit, NJ – sequence: 13 givenname: Gerald surname: Marit fullname: Marit, Gerald organization: Philip L. McCarthy, Roswell Park Cancer Institute, Buffalo, NY; Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; Maria Teresa Petrucci, University La Sapienza; Antonio Palumbo, Takeda Italia, Rome; Patrizia Tosi, Rimini Hospital, Rimini; Sara Bringhen and Francesca Gay, University of Torino, Torino; Pellegrino Musto, Cancer Institute for Research and Care and The Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; Cyrille Hulin and Gerald Marit, Bordeaux Centre Hospitalier Universitaire, Bordeaux; Denis Caillot, Dijon University Hospital Center, Dijon; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes; Michel Attal, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Sin-Ho Jung, Duke University, Durham, NC; and Zhinuan Yu, Benjamin Winograd, and Robert D. Knight, Celgene Corporation, Summit, NJ – sequence: 14 givenname: Sin-Ho surname: Jung fullname: Jung, Sin-Ho organization: Philip L. McCarthy, Roswell Park Cancer Institute, Buffalo, NY; Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; Maria Teresa Petrucci, University La Sapienza; Antonio Palumbo, Takeda Italia, Rome; Patrizia Tosi, Rimini Hospital, Rimini; Sara Bringhen and Francesca Gay, University of Torino, Torino; Pellegrino Musto, Cancer Institute for Research and Care and The Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; Cyrille Hulin and Gerald Marit, Bordeaux Centre Hospitalier Universitaire, Bordeaux; Denis Caillot, Dijon University Hospital Center, Dijon; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes; Michel Attal, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Sin-Ho Jung, Duke University, Durham, NC; and Zhinuan Yu, Benjamin Winograd, and Robert D. Knight, Celgene Corporation, Summit, NJ – sequence: 15 givenname: Zhinuan surname: Yu fullname: Yu, Zhinuan organization: Philip L. McCarthy, Roswell Park Cancer Institute, Buffalo, NY; Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; Maria Teresa Petrucci, University La Sapienza; Antonio Palumbo, Takeda Italia, Rome; Patrizia Tosi, Rimini Hospital, Rimini; Sara Bringhen and Francesca Gay, University of Torino, Torino; Pellegrino Musto, Cancer Institute for Research and Care and The Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; Cyrille Hulin and Gerald Marit, Bordeaux Centre Hospitalier Universitaire, Bordeaux; Denis Caillot, Dijon University Hospital Center, Dijon; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes; Michel Attal, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Sin-Ho Jung, Duke University, Durham, NC; and Zhinuan Yu, Benjamin Winograd, and Robert D. Knight, Celgene Corporation, Summit, NJ – sequence: 16 givenname: Benjamin surname: Winograd fullname: Winograd, Benjamin organization: Philip L. McCarthy, Roswell Park Cancer Institute, Buffalo, NY; Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; Maria Teresa Petrucci, University La Sapienza; Antonio Palumbo, Takeda Italia, Rome; Patrizia Tosi, Rimini Hospital, Rimini; Sara Bringhen and Francesca Gay, University of Torino, Torino; Pellegrino Musto, Cancer Institute for Research and Care and The Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; Cyrille Hulin and Gerald Marit, Bordeaux Centre Hospitalier Universitaire, Bordeaux; Denis Caillot, Dijon University Hospital Center, Dijon; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes; Michel Attal, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Sin-Ho Jung, Duke University, Durham, NC; and Zhinuan Yu, Benjamin Winograd, and Robert D. Knight, Celgene Corporation, Summit, NJ – sequence: 17 givenname: Robert D surname: Knight fullname: Knight, Robert D organization: Philip L. McCarthy, Roswell Park Cancer Institute, Buffalo, NY; Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; Maria Teresa Petrucci, University La Sapienza; Antonio Palumbo, Takeda Italia, Rome; Patrizia Tosi, Rimini Hospital, Rimini; Sara Bringhen and Francesca Gay, University of Torino, Torino; Pellegrino Musto, Cancer Institute for Research and Care and The Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; Cyrille Hulin and Gerald Marit, Bordeaux Centre Hospitalier Universitaire, Bordeaux; Denis Caillot, Dijon University Hospital Center, Dijon; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes; Michel Attal, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Sin-Ho Jung, Duke University, Durham, NC; and Zhinuan Yu, Benjamin Winograd, and Robert D. Knight, Celgene Corporation, Summit, NJ – sequence: 18 givenname: Antonio surname: Palumbo fullname: Palumbo, Antonio organization: Philip L. McCarthy, Roswell Park Cancer Institute, Buffalo, NY; Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; Maria Teresa Petrucci, University La Sapienza; Antonio Palumbo, Takeda Italia, Rome; Patrizia Tosi, Rimini Hospital, Rimini; Sara Bringhen and Francesca Gay, University of Torino, Torino; Pellegrino Musto, Cancer Institute for Research and Care and The Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; Cyrille Hulin and Gerald Marit, Bordeaux Centre Hospitalier Universitaire, Bordeaux; Denis Caillot, Dijon University Hospital Center, Dijon; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes; Michel Attal, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Sin-Ho Jung, Duke University, Durham, NC; and Zhinuan Yu, Benjamin Winograd, and Robert D. Knight, Celgene Corporation, Summit, NJ – sequence: 19 givenname: Michel surname: Attal fullname: Attal, Michel organization: Philip L. McCarthy, Roswell Park Cancer Institute, Buffalo, NY; Sarah A. Holstein, University of Nebraska Medical Center, Omaha, NE; Maria Teresa Petrucci, University La Sapienza; Antonio Palumbo, Takeda Italia, Rome; Patrizia Tosi, Rimini Hospital, Rimini; Sara Bringhen and Francesca Gay, University of Torino, Torino; Pellegrino Musto, Cancer Institute for Research and Care and The Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; Cyrille Hulin and Gerald Marit, Bordeaux Centre Hospitalier Universitaire, Bordeaux; Denis Caillot, Dijon University Hospital Center, Dijon; Philippe Moreau, University Hospital Hôtel-Dieu, Nantes; Michel Attal, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France; Sin-Ho Jung, Duke University, Durham, NC; and Zhinuan Yu, Benjamin Winograd, and Robert D. Knight, Celgene Corporation, Summit, NJ
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/28742454$$D View this record in MEDLINE/PubMed
BookMark	eNpNkM1PhDAUxBuzxv3QuyfToxew7RYK3gh-Z9c9uJ5JgcemprRIS5T_XhLXxNO8TCbz8pslmhlrAKFLSkLKCLl5yXchI1SEgoVxLNITtKARE4EQUTT7d8_R0rkPQihP1tEZmrNEcMYjvkDfGzBSq9q2qga8lcr4yTAV4Kzx0ONs8Fbbgx0cfvPQBjlojfe9NK7T0njplTVYGfwKX3rEd0oejHVQ4-2gver0VDmCtq28xRnegpdBNr0bnXLn6LSR2sHFUVfo_eF-nz8Fm93jc55tgoqz2AcJqSARUnBBWEoEY2USi4jSMknrkkoqqzKtKiHjmEVENtBwXtKSMEohmiDXbIWuf3u73n4O4HzRKldNFNLARFXQlK2nMRLOp-jVMTqULdRF16tW9mPxtxb7AcEEboY
CitedBy_id	crossref_primary_10_3389_fonc_2022_932852 crossref_primary_10_1002_cam4_70619 crossref_primary_10_1111_bjh_15426 crossref_primary_10_1186_s41687_024_00691_2 crossref_primary_10_1038_s41375_018_0359_7 crossref_primary_10_1111_ejh_14316 crossref_primary_10_3390_cancers13184706 crossref_primary_10_1177_20406207211019622 crossref_primary_10_1007_s00277_020_04149_5 crossref_primary_10_3389_fonc_2021_682658 crossref_primary_10_1038_s41408_020_0311_8 crossref_primary_10_1007_s12185_023_03602_1 crossref_primary_10_2217_fon_2020_0907 crossref_primary_10_1007_s00432_021_03668_6 crossref_primary_10_1038_s41409_018_0112_x crossref_primary_10_1016_j_clml_2024_10_012 crossref_primary_10_3389_fonc_2023_1078725 crossref_primary_10_4081_hr_2020_8954 crossref_primary_10_1038_s41467_020_16805_5 crossref_primary_10_1200_JCO_18_02096 crossref_primary_10_1016_j_jgo_2020_07_007 crossref_primary_10_1016_j_bbmt_2020_08_017 crossref_primary_10_1097_TP_0000000000002449 crossref_primary_10_1007_s12254_018_0383_3 crossref_primary_10_1016_j_jtct_2023_06_015 crossref_primary_10_1038_s41409_019_0697_8 crossref_primary_10_1177_1073274819870549 crossref_primary_10_1159_000487043 crossref_primary_10_1080_10428194_2021_1948030 crossref_primary_10_2147_BLCTT_S327016 crossref_primary_10_1007_s00761_024_01652_6 crossref_primary_10_1016_S1470_2045_22_00738_0 crossref_primary_10_1080_13506129_2021_1978423 crossref_primary_10_1158_1078_0432_CCR_20_0841 crossref_primary_10_3390_cancers14184492 crossref_primary_10_1016_j_blre_2023_101116 crossref_primary_10_1182_bloodadvances_2023011601 crossref_primary_10_1200_EDBK_280221 crossref_primary_10_1038_s41408_025_01253_5 crossref_primary_10_1016_j_bbmt_2018_11_001 crossref_primary_10_1016_j_clml_2023_07_001 crossref_primary_10_1111_ejh_13231 crossref_primary_10_1080_14737140_2022_2069564 crossref_primary_10_1111_ejh_13596 crossref_primary_10_1016_j_bbmt_2018_03_012 crossref_primary_10_1182_bloodadvances_2023009658 crossref_primary_10_3390_cancers13194867 crossref_primary_10_3390_medicina61050859 crossref_primary_10_1016_j_apsb_2025_09_009 crossref_primary_10_1111_bjh_15759 crossref_primary_10_3389_fonc_2022_1000106 crossref_primary_10_3390_jcm10112261 crossref_primary_10_1007_s10147_019_01436_8 crossref_primary_10_1016_j_jtct_2022_04_022 crossref_primary_10_1007_s00520_024_08663_4 crossref_primary_10_1182_blood_2022018339 crossref_primary_10_1182_blood_2024027342 crossref_primary_10_1038_nrclinonc_2017_135 crossref_primary_10_1080_10428194_2025_2547986 crossref_primary_10_1158_1078_0432_CCR_23_2194 crossref_primary_10_1053_j_seminoncol_2022_01_011 crossref_primary_10_1080_10428194_2019_1672058 crossref_primary_10_1038_s41409_020_0844_2 crossref_primary_10_1016_j_jgo_2019_05_014 crossref_primary_10_12998_wjcc_v10_i32_11712 crossref_primary_10_3390_ijms23147627 crossref_primary_10_1182_blood_2022019531 crossref_primary_10_3390_jpm13030412 crossref_primary_10_1038_s41375_020_0948_0 crossref_primary_10_1002_ajh_25507 crossref_primary_10_1038_s41571_021_00581_2 crossref_primary_10_1080_14737140_2019_1674142 crossref_primary_10_1080_10428194_2020_1747066 crossref_primary_10_1016_j_semnephrol_2024_151497 crossref_primary_10_4155_tde_2021_0041 crossref_primary_10_1158_1078_0432_CCR_21_3420 crossref_primary_10_1016_j_modpat_2023_100166 crossref_primary_10_1038_s41409_021_01455_y crossref_primary_10_3390_cancers17152439 crossref_primary_10_1080_14737140_2018_1496823 crossref_primary_10_1016_j_yao_2022_02_012 crossref_primary_10_1080_17512433_2022_2032656 crossref_primary_10_1080_14737140_2023_2213891 crossref_primary_10_1002_phar_2407 crossref_primary_10_1177_2040620719888111 crossref_primary_10_1136_bmjopen_2022_063037 crossref_primary_10_1111_bjh_19097 crossref_primary_10_1038_s41571_021_00479_z crossref_primary_10_1002_acg2_59 crossref_primary_10_1016_S2352_3026_22_00289_7 crossref_primary_10_1002_cncr_34211 crossref_primary_10_1093_clinchem_hvae136 crossref_primary_10_1155_2018_9052314 crossref_primary_10_1182_bloodadvances_2018017186 crossref_primary_10_1038_s41409_018_0264_8 crossref_primary_10_1200_EDBK_238527 crossref_primary_10_1111_ejh_13678 crossref_primary_10_1016_S0140_6736_20_30734_0 crossref_primary_10_1007_s00277_023_05148_y crossref_primary_10_7759_cureus_16372 crossref_primary_10_1016_j_blre_2020_100757 crossref_primary_10_1016_j_clml_2018_05_019 crossref_primary_10_1016_S0140_6736_18_33003_4 crossref_primary_10_1001_jama_2022_0003 crossref_primary_10_1080_14740338_2020_1733968 crossref_primary_10_1016_S2352_3026_21_00140_X crossref_primary_10_1146_annurev_med_050522_033815 crossref_primary_10_1080_10428194_2023_2234527 crossref_primary_10_1016_j_jtct_2022_03_019 crossref_primary_10_1007_s00277_019_03609_x crossref_primary_10_1097_PPO_0000000000000348 crossref_primary_10_1016_j_clml_2018_02_015 crossref_primary_10_1007_s12185_020_02829_6 crossref_primary_10_1016_S1470_2045_18_30687_9 crossref_primary_10_1007_s00277_019_03815_7 crossref_primary_10_3390_cancers12010012 crossref_primary_10_1007_s00432_023_05137_8 crossref_primary_10_1016_j_bbmt_2020_03_028 crossref_primary_10_1080_16078454_2024_2432815 crossref_primary_10_1080_17474086_2020_1739517 crossref_primary_10_1007_s15004_020_8150_0 crossref_primary_10_1016_j_leukres_2023_107324 crossref_primary_10_1016_S0140_6736_21_00135_5 crossref_primary_10_1080_17474086_2025_2525457 crossref_primary_10_1016_j_jtct_2023_08_006 crossref_primary_10_1007_s15004_025_0955_4 crossref_primary_10_1002_cam4_5422 crossref_primary_10_1016_j_clml_2019_04_018 crossref_primary_10_1038_s41409_019_0534_0 crossref_primary_10_1016_j_bbmt_2018_01_006 crossref_primary_10_1016_j_jtct_2022_07_028 crossref_primary_10_1038_s41408_020_00400_4 crossref_primary_10_1007_s00277_020_04340_8 crossref_primary_10_1080_14712598_2020_1802422 crossref_primary_10_1038_s41467_023_40966_8 crossref_primary_10_1080_10428194_2025_2551785 crossref_primary_10_1002_hon_2923 crossref_primary_10_1016_j_bbmt_2019_11_018 crossref_primary_10_1002_cam4_6640 crossref_primary_10_1007_s00277_020_04023_4 crossref_primary_10_1016_j_jcyt_2023_05_015 crossref_primary_10_1038_s41409_024_02200_x crossref_primary_10_1080_14789450_2022_2142564 crossref_primary_10_1038_s41409_020_01007_w crossref_primary_10_1080_10428194_2023_2255325 crossref_primary_10_1038_s41408_019_0200_1 crossref_primary_10_3390_jcm8060877 crossref_primary_10_1016_j_bbmt_2020_03_006 crossref_primary_10_1080_10428194_2019_1633633 crossref_primary_10_1097_HS9_0000000000000242 crossref_primary_10_3390_biomedicines11072087 crossref_primary_10_1080_10428194_2019_1633639 crossref_primary_10_1002_ajh_25764 crossref_primary_10_3390_hemato1020008 crossref_primary_10_1186_s12885_019_5600_x crossref_primary_10_1080_10428194_2020_1798952 crossref_primary_10_1186_s13643_020_01318_5 crossref_primary_10_1038_s41408_020_00390_3 crossref_primary_10_1634_theoncologist_2017_0440 crossref_primary_10_1172_JCI98765 crossref_primary_10_1177_2399369320905604 crossref_primary_10_1080_17474086_2019_1634541 crossref_primary_10_1007_s40487_021_00143_7 crossref_primary_10_1016_j_clml_2020_06_002 crossref_primary_10_3390_cancers13071668 crossref_primary_10_1007_s11899_021_00631_7 crossref_primary_10_1038_s41408_018_0141_0 crossref_primary_10_1080_10428194_2025_2455485 crossref_primary_10_1111_bjh_18295 crossref_primary_10_2217_ijh_2018_0004 crossref_primary_10_3389_fonc_2021_703233 crossref_primary_10_1182_bloodadvances_2022007218 crossref_primary_10_1111_ejh_14355 crossref_primary_10_1158_2326_6066_CIR_20_0663 crossref_primary_10_1038_s41409_020_01026_7 crossref_primary_10_21320_2500_2139_2018_11_4_360_367 crossref_primary_10_1038_s41375_020_0819_8 crossref_primary_10_7759_cureus_47460 crossref_primary_10_1016_S1470_2045_18_30764_2 crossref_primary_10_1038_s41409_018_0269_3 crossref_primary_10_1016_S2352_3026_18_30154_6 crossref_primary_10_1016_S2352_3026_20_30099_5 crossref_primary_10_1038_s41409_019_0663_5 crossref_primary_10_1097_MD_0000000000038609 crossref_primary_10_3390_ph13120451 crossref_primary_10_1200_EDBK_433520 crossref_primary_10_1111_ejh_13496 crossref_primary_10_1007_s00277_019_03772_1 crossref_primary_10_1007_s10238_023_01100_6 crossref_primary_10_1016_S2352_3026_17_30148_5 crossref_primary_10_1111_ejh_13497 crossref_primary_10_1111_imj_70148 crossref_primary_10_1111_ejh_13379 crossref_primary_10_1182_blood_2021011670 crossref_primary_10_1038_s41409_024_02462_5 crossref_primary_10_3892_ijmm_2021_5046 crossref_primary_10_1080_10428194_2020_1832672 crossref_primary_10_5604_01_3001_0013_6907 crossref_primary_10_1093_jjco_hyz083 crossref_primary_10_3390_cancers13235886 crossref_primary_10_1007_s40265_017_0795_0 crossref_primary_10_3389_fonc_2020_624661 crossref_primary_10_1016_j_jtct_2021_10_022 crossref_primary_10_1038_s41408_024_01136_1 crossref_primary_10_1080_10428194_2018_1523399 crossref_primary_10_1016_j_beha_2019_02_003 crossref_primary_10_1080_17474086_2018_1537776 crossref_primary_10_1111_ejh_13281 crossref_primary_10_1002_jcph_1602 crossref_primary_10_1016_S0140_6736_18_33128_3 crossref_primary_10_1053_j_seminoncol_2021_11_003 crossref_primary_10_1080_10428194_2022_2123231 crossref_primary_10_4103_ijc_ijc_78_22 crossref_primary_10_1080_17474086_2021_1905513 crossref_primary_10_1016_S2352_3026_22_00334_9 crossref_primary_10_1038_s41375_022_01691_1 crossref_primary_10_1182_blood_2022019352 crossref_primary_10_1111_bjh_19353 crossref_primary_10_1097_HS9_0000000000000163 crossref_primary_10_1182_bloodadvances_2021006498 crossref_primary_10_1007_s12185_019_02764_1 crossref_primary_10_3390_cancers11111819 crossref_primary_10_1080_17843286_2020_1860411 crossref_primary_10_3390_cancers12102885 crossref_primary_10_1002_ajh_27451 crossref_primary_10_3390_cancers13235949 crossref_primary_10_4103_sjkdt_sjkdt_333_22 crossref_primary_10_1002_cncr_31718 crossref_primary_10_1056_NEJMe2314067 crossref_primary_10_1080_14737140_2020_1708721 crossref_primary_10_1007_s12254_025_01030_x crossref_primary_10_3390_cancers15215157 crossref_primary_10_1038_s41408_018_0147_7 crossref_primary_10_1080_10428194_2020_1719091 crossref_primary_10_3390_cells14110776 crossref_primary_10_1016_j_trf_2024_06_014 crossref_primary_10_1200_OP_21_00210 crossref_primary_10_1002_ajh_26596 crossref_primary_10_1182_bloodadvances_2019000539 crossref_primary_10_1038_s41408_020_0298_1 crossref_primary_10_1016_j_jtct_2023_11_001 crossref_primary_10_1002_ajh_27206 crossref_primary_10_1002_ajh_27327 crossref_primary_10_1080_10428194_2020_1749603 crossref_primary_10_1016_j_clml_2019_10_014 crossref_primary_10_3389_fonc_2022_844779 crossref_primary_10_1016_j_clinthera_2018_05_017 crossref_primary_10_1016_S2352_3026_18_30149_2 crossref_primary_10_1038_s41571_023_00801_x crossref_primary_10_1177_10781552221150935 crossref_primary_10_1080_17474086_2020_1839886 crossref_primary_10_1016_S2352_3026_24_00277_1 crossref_primary_10_3390_life13112229 crossref_primary_10_1007_s12325_021_01824_5 crossref_primary_10_1016_j_bbmt_2019_09_005 crossref_primary_10_1007_s15004_019_6651_5 crossref_primary_10_1016_j_bbmt_2017_12_781 crossref_primary_10_1111_bjh_19326 crossref_primary_10_1016_j_canlet_2024_216900 crossref_primary_10_1016_S1470_2045_21_00428_9 crossref_primary_10_3390_medsci9010003 crossref_primary_10_1002_ajh_25497 crossref_primary_10_1007_s12185_023_03631_w crossref_primary_10_1097_PPO_0000000000000524 crossref_primary_10_1177_10781552221112320 crossref_primary_10_1158_0008_5472_CAN_17_2446 crossref_primary_10_1182_blood_2022016853 crossref_primary_10_1200_JCO_18_00685 crossref_primary_10_1158_1078_0432_CCR_21_1916 crossref_primary_10_1182_bloodadvances_2021005532 crossref_primary_10_1016_j_annonc_2020_11_014 crossref_primary_10_1007_s12288_020_01255_2 crossref_primary_10_1038_s41409_018_0216_3 crossref_primary_10_1136_bcr_2022_249637 crossref_primary_10_3390_cancers11111735 crossref_primary_10_1111_bjh_16287 crossref_primary_10_1182_blood_2020008734 crossref_primary_10_1016_j_clml_2020_05_027 crossref_primary_10_1182_blood_2020008733 crossref_primary_10_1111_imj_15842 crossref_primary_10_1182_bloodadvances_2022007496 crossref_primary_10_1016_j_lpm_2024_104262 crossref_primary_10_1002_cam4_2695 crossref_primary_10_1177_2040620718822660 crossref_primary_10_1038_s41408_024_00978_z crossref_primary_10_1182_blood_2020008735 crossref_primary_10_1016_j_bbmt_2017_12_774 crossref_primary_10_1016_j_hoc_2023_12_006 crossref_primary_10_5694_mja2_50129 crossref_primary_10_3389_fonc_2022_936993 crossref_primary_10_3389_fphar_2018_01357 crossref_primary_10_1038_leu_2017_331 crossref_primary_10_1016_S2352_3026_20_30354_9 crossref_primary_10_1080_10428194_2021_1992763 crossref_primary_10_1182_bloodadvances_2020002827 crossref_primary_10_1186_s12885_019_6286_9 crossref_primary_10_3390_cancers12020265 crossref_primary_10_1038_s41408_021_00474_8 crossref_primary_10_1007_s00277_020_04316_8 crossref_primary_10_1007_s41669_022_00344_4 crossref_primary_10_2147_ITT_S240886 crossref_primary_10_1038_s41571_018_0018_y crossref_primary_10_1002_cam4_7071 crossref_primary_10_1038_s41409_024_02455_4 crossref_primary_10_1002_cam4_7193 crossref_primary_10_1159_000496589 crossref_primary_10_1016_S2352_3026_21_00130_7 crossref_primary_10_3390_cancers15051605 crossref_primary_10_3390_cancers16051024 crossref_primary_10_1038_s41409_021_01371_1 crossref_primary_10_1182_bloodadvances_2020002838 crossref_primary_10_1182_bloodadvances_2020001508 crossref_primary_10_3390_cells9030601 crossref_primary_10_1016_j_clml_2024_12_001 crossref_primary_10_1182_bloodadvances_2022009138 crossref_primary_10_1016_j_jtct_2021_06_014 crossref_primary_10_1016_j_jtct_2024_12_023 crossref_primary_10_1016_j_bbmt_2018_08_013 crossref_primary_10_1016_S1470_2045_20_30756_7 crossref_primary_10_2147_JBM_S434055 crossref_primary_10_3390_cancers13040863 crossref_primary_10_1038_s41408_023_00794_x crossref_primary_10_1016_j_beha_2020_101144 crossref_primary_10_3390_cancers15082203 crossref_primary_10_1093_oncolo_oyad110 crossref_primary_10_1111_bjh_16139 crossref_primary_10_1111_bjh_16130 crossref_primary_10_1080_10428194_2020_1725504 crossref_primary_10_1007_s00108_018_0527_x crossref_primary_10_1038_s41409_018_0214_5 crossref_primary_10_1038_s41408_024_01156_x crossref_primary_10_1056_NEJMoa2204925 crossref_primary_10_1038_s41408_023_00804_y crossref_primary_10_1080_17474086_2019_1576521 crossref_primary_10_1002_cam4_2656 crossref_primary_10_1182_blood_2018_08_825349 crossref_primary_10_1186_s40364_021_00344_2 crossref_primary_10_1016_j_beha_2020_101150 crossref_primary_10_1159_000539225 crossref_primary_10_1016_j_jtct_2024_06_001 crossref_primary_10_1080_17474086_2020_1804356 crossref_primary_10_2217_fon_2019_0380 crossref_primary_10_2217_fon_2023_0120 crossref_primary_10_1016_j_jtct_2023_09_014 crossref_primary_10_1016_j_jtct_2022_07_007 crossref_primary_10_1016_j_jtct_2022_03_020 crossref_primary_10_1016_j_bbmt_2019_01_009 crossref_primary_10_1007_s00277_023_05443_8 crossref_primary_10_1182_bloodadvances_2021005941 crossref_primary_10_1111_bjh_18772 crossref_primary_10_1111_ejh_13506 crossref_primary_10_1038_s41408_022_00640_6 crossref_primary_10_1186_s40425_018_0491_y crossref_primary_10_1111_ejh_13981 crossref_primary_10_1038_s41375_020_0976_9 crossref_primary_10_1007_s13273_023_00415_5 crossref_primary_10_1038_s41571_024_00895_x crossref_primary_10_1182_blood_2019003749 crossref_primary_10_1038_s41408_024_01062_2 crossref_primary_10_1080_14740338_2021_1945578 crossref_primary_10_1016_j_bbmt_2019_07_004 crossref_primary_10_1016_j_blre_2021_100887 crossref_primary_10_3390_cancers12113488 crossref_primary_10_1038_s41408_020_0326_1 crossref_primary_10_1016_j_clml_2022_11_007 crossref_primary_10_1038_s41408_020_00353_8 crossref_primary_10_1038_s41572_024_00529_7 crossref_primary_10_1002_jha2_284 crossref_primary_10_1186_s12885_025_13518_0 crossref_primary_10_3390_jcm9113437 crossref_primary_10_1016_S2352_3026_20_30355_0 crossref_primary_10_1016_j_bneo_2024_100042 crossref_primary_10_1007_s00277_021_04475_2 crossref_primary_10_1182_blood_2024027686 crossref_primary_10_1007_s00761_020_00780_z crossref_primary_10_1007_s11523_024_01122_4 crossref_primary_10_1177_2040620718775629 crossref_primary_10_1007_s00761_018_0393_0 crossref_primary_10_1016_j_blre_2021_100869 crossref_primary_10_1038_s41375_020_0930_x crossref_primary_10_1002_acg2_95 crossref_primary_10_1002_acg2_96 crossref_primary_10_1038_s41409_022_01631_8 crossref_primary_10_1007_s00520_020_05539_1 crossref_primary_10_1016_j_ctrv_2019_101929 crossref_primary_10_1080_10428194_2018_1473577 crossref_primary_10_1038_s41409_019_0749_0 crossref_primary_10_1007_s12288_025_02045_4 crossref_primary_10_1016_j_tranon_2022_101448 crossref_primary_10_1080_14737140_2018_1490181 crossref_primary_10_1111_bjh_17410 crossref_primary_10_1002_ajh_27029 crossref_primary_10_1007_s12185_020_02869_y crossref_primary_10_3390_cancers15225335 crossref_primary_10_1182_blood_2024027674 crossref_primary_10_1053_j_seminoncol_2022_01_009 crossref_primary_10_1080_14656566_2017_1409207 crossref_primary_10_3389_fneur_2023_1098930 crossref_primary_10_1080_10428194_2024_2358857 crossref_primary_10_1016_S2352_3026_17_30140_0 crossref_primary_10_1038_s41408_019_0205_9 crossref_primary_10_1007_s00432_019_03101_z crossref_primary_10_1016_j_bbmt_2018_12_002 crossref_primary_10_1111_bjh_18614 crossref_primary_10_3390_jcm9113778 crossref_primary_10_1200_JCO_23_00934 crossref_primary_10_1007_s11899_021_00616_6 crossref_primary_10_1007_s40265_021_01514_0 crossref_primary_10_1177_15330338251321349 crossref_primary_10_1111_ecc_13481 crossref_primary_10_1016_j_ejca_2018_09_011 crossref_primary_10_1159_000501298 crossref_primary_10_1002_hem3_106 crossref_primary_10_1182_blood_2025028814 crossref_primary_10_3389_frhem_2024_1436845 crossref_primary_10_1016_j_ctrv_2021_102284 crossref_primary_10_1038_s41375_019_0383_2 crossref_primary_10_1182_bloodadvances_2023010051 crossref_primary_10_1038_s41409_018_0284_4 crossref_primary_10_1016_S2352_3026_20_30323_9 crossref_primary_10_1111_bjh_18600 crossref_primary_10_1200_EDBK_205443 crossref_primary_10_1016_j_ctarc_2021_100444 crossref_primary_10_1007_s00277_020_03988_6 crossref_primary_10_1080_10428194_2019_1627537 crossref_primary_10_1080_10428194_2020_1811275 crossref_primary_10_1111_bjh_17504 crossref_primary_10_1177_2040620718761776 crossref_primary_10_1016_S1470_2045_21_00490_3 crossref_primary_10_1093_ajcp_aqaa109 crossref_primary_10_3390_cells11040606 crossref_primary_10_1007_s12185_018_2543_y crossref_primary_10_1111_ejh_13602 crossref_primary_10_1016_S1470_2045_21_00535_0 crossref_primary_10_2217_fon_2019_0422 crossref_primary_10_1002_cncr_33409 crossref_primary_10_1016_j_jtct_2022_01_026 crossref_primary_10_1038_s41409_020_0791_y crossref_primary_10_1038_s41408_021_00548_7 crossref_primary_10_1200_JCO_2017_74_7014 crossref_primary_10_1038_s41375_020_0724_1 crossref_primary_10_1038_s41408_023_00905_8 crossref_primary_10_3390_cancers11122015 crossref_primary_10_1038_s41408_020_0273_x crossref_primary_10_1159_000505991 crossref_primary_10_3390_cancers12123576 crossref_primary_10_1016_j_clml_2020_01_010 crossref_primary_10_1007_s12185_023_03682_z crossref_primary_10_1002_advs_202308617 crossref_primary_10_1080_17474086_2018_1518129 crossref_primary_10_12998_wjcc_v8_i19_4579
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1200/JCO.2017.72.6679
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine Pharmacy, Therapeutics, & Pharmacology
EISSN	1527-7755
ExternalDocumentID	28742454
Genre	Meta-Analysis Journal Article
GrantInformation_xml	– fundername: NCI NIH HHS grantid: U10 CA180821 – fundername: NCI NIH HHS grantid: U10 CA180882
GroupedDBID	--- .55 0R~ 18M 2WC 34G 39C 4.4 53G 5GY 5RE 8F7 AARDX AAWTL AAYEP AAYOK ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AIAGR ALMA_UNASSIGNED_HOLDINGS AWKKM BAWUL BYPQX C45 CGR CS3 CUY CVF DIK EBS ECM EIF EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 K-O KQ8 L7B LSO MJL N9A NPM O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN SV3 TEORI TR2 TWZ UDS VVN WH7 X7M YCJ YFH YQY 7X8 ABBLC
ID	FETCH-LOGICAL-c426t-80ce87a7470290722b867511b89db1a1acb9cc7a66250afef44b1b0211e587432
IEDL.DBID	7X8
ISICitedReferencesCount	523
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000412454000004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1527-7755
IngestDate	Wed Oct 01 13:23:31 EDT 2025 Thu Jan 02 22:59:36 EST 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	29
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c426t-80ce87a7470290722b867511b89db1a1acb9cc7a66250afef44b1b0211e587432
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	http://ascopubs.org/doi/pdf/10.1200/JCO.2017.72.6679
PMID	28742454
PQID	1923742844
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1923742844 pubmed_primary_28742454
PublicationCentury	2000
PublicationDate	2017-10-10
PublicationDateYYYYMMDD	2017-10-10
PublicationDate_xml	– month: 10 year: 2017 text: 2017-10-10 day: 10
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Journal of clinical oncology
PublicationTitleAlternate	J Clin Oncol
PublicationYear	2017
References	28834440 - J Clin Oncol. 2017 Oct 10;35(29):3269-3271
References_xml	– reference: 28834440 - J Clin Oncol. 2017 Oct 10;35(29):3269-3271
SSID	ssj0014835
Score	2.6785965
SecondaryResourceType	review_article
Snippet	Purpose Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) demonstrated prolonged progression-free survival (PFS) versus...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	3279
SubjectTerms	Adult Aged Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - adverse effects Chemotherapy, Adjuvant Disease Progression Disease-Free Survival Drug Administration Schedule Female Humans Kaplan-Meier Estimate Lenalidomide Maintenance Chemotherapy Male Middle Aged Multiple Myeloma - diagnosis Multiple Myeloma - mortality Multiple Myeloma - therapy Randomized Controlled Trials as Topic Risk Factors Stem Cell Transplantation - adverse effects Stem Cell Transplantation - mortality Thalidomide - administration & dosage Thalidomide - adverse effects Thalidomide - analogs & derivatives Time Factors Transplantation, Autologous Treatment Outcome Young Adult
Title	Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
URI	https://www.ncbi.nlm.nih.gov/pubmed/28742454 https://www.proquest.com/docview/1923742844
Volume	35
WOSCitedRecordID	wos000412454000004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Na9tAEF2aJoRcksb57EeYQvApSrzKSrvqJRi3JoTKMcQB38x-jMAgS0nshPrfd1aS8S0UetFJC9JqtPPezux7jJ0nwjiBDgPKHZIISqwCIy0G2TW3aKJEGZdVZhNyMFDjcTJsNtzmTVvlak2sFmpXWr9HfuWRCNE4JcTN03PgXaN8dbWx0Nhgm9cEZXxUy_G6iiBUZbDpnVsJRUZRU6akwLi66937vi55KcPLOJbvAMwq0fT3_vcRP7HdBmJCt46JffYBixbbTpsieou1h7Vc9fICRuvTV_MLaMNwLWS9PGB_fqOH6a6cTR1Cqr20hNfnQOh6Z3Hovlbmt-XrHB4WOAt6mOdQq6Xnuj7SVMC0AFpI8yX8rJv60EHaNDFCusS8nOkf0IUUFzpYKaQcssf-r1HvNmicGgJLGX5Bac6ikpqoSSckth2GRhER4dyoxBmuubYmsVbqmNhWR2eYCWG4IXjBMVKEYcIj9rEoCzxhIAgQxTpzQidEjUSm6ObYhrFDTmN0eMq-ryZ_Qn-CL2_oAulNJ-vpP2XH9RecPNWSHROv6h-KSHz-h9Ff2I6PDJ-geOcr28xoHcBvbMu-Labzl7MqxOg6GKZ_ASnV3F4
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Lenalidomide+Maintenance+After+Autologous+Stem-Cell+Transplantation+in+Newly+Diagnosed+Multiple+Myeloma%3A+A+Meta-Analysis&rft.jtitle=Journal+of+clinical+oncology&rft.au=McCarthy%2C+Philip+L&rft.au=Holstein%2C+Sarah+A&rft.au=Petrucci%2C+Maria+Teresa&rft.au=Richardson%2C+Paul+G&rft.date=2017-10-10&rft.issn=1527-7755&rft.eissn=1527-7755&rft.volume=35&rft.issue=29&rft.spage=3279&rft_id=info:doi/10.1200%2FJCO.2017.72.6679&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-7755&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-7755&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-7755&client=summon